TOKYO, Oct. 18, 2024 /PRNewswire/ -- STAYGE Labs, an entertainment tech startup has officially launched 'LiNC,' a fandom communication platform designed to help artists connect more closely and easily with their core fans. LiNC not only strengthens artist-fan relationships but also offers tools that help artists efficiently manage and grow their fanbase.
LiNC provides two key features. First, 'Private Messaging and One-on-One Video Calls'. Fans can engage with artists through a familiar messenger interface, joining chat rooms for free to receive updates and news. LiNC also includes a paid subscription option, enabling artists to share exclusive content and further build their fandom.
Secondly, 'Efficient Fan Management for Artists'. For artists and their teams, the platform simplifies managing multiple one-on-one video calls with fans. With just a simple click, managers can oversee numerous video interactions simultaneously, eliminating the hassle of manually adjusting cameras or smartphones.
Before the official launch, STAYGE Labs ran a successful beta test featuring a one-on-one video call event with South Korean actor Park Bo-gum and 100 fans through a previous version of the app called 'youmeOn.' During the beta phase, over 100 online events with K-pop artists took place, proving the platform's potential. Several K-pop artists participated in the beta and actively connected with their fans.
This year, STAYGE Labs plans to expand further by establishing a subsidiary in Tokyo, aiming to enter the Japanese market. The company also plans to bring J-pop artists, actors, and athletes to the platform, enhancing its reach across different entertainment sectors.
Baeg Myung-hyun, CEO of STAYGE Labs, said, "LiNC is designed to foster close relationships between artists and fans while offering a powerful tool for promoting their activities. Our goal is to create a win-win scenario where artists can build loyal core fanbases, and fans enjoy exclusive interactions." He further emphasized that the company will continue improving the platform and focusing on global market expansion, particularly in Japan.
About STAYGE Labs
STAYGE Labs has been at the forefront of innovation in the entertainment industry for the past eight years. In 2021, the company entered into a strategic partnership with CJ ENM, and by 2022, it successfully launched the K-pop culture platform 'Mnet Plus,' which now serves over 10 million global users. STAYGE Labs excels in managing large-scale fan engagement platforms, leveraging its advanced technology and expertise. The company is also expanding into Japan with its subsidiary, STAYGE NXT Lab.
For more information, visit:
STAYGE NXT Lab Homepage: https://stayge.io/ja
LiNC Homepage: https://www.stayge.io/ja/linc
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Entertainment Tech Startup STAYGE Labs Launches 'LiNC' App, Connecting Artists with Core Fans
The site will add state-of-the-art CGT capacity and employ artificial intelligence and automation to achieve critical product supply efficiencies for North American and global biotherapy clients
HAMILTON, ON, Oct. 18, 2024 /PRNewswire/ -- Today OmniaBio Inc. will announce the opening of a new North American cell and gene therapy (CGT) manufacturing and artificial intelligence (AI) centre of excellence, which is now Canada's largest contract development and manufacturing organization (CDMO) facility dedicated to CGT. Based in Hamilton, Ontario, the facility is a groundbreaking development for both the Canadian biotech industry and the broader global market.
This commercial-ready facility will enhance the manufacturing of these transformative therapies, further establishing Canada as a hub for innovation, while increasing access and affordability to advanced medical treatments across North America. Initially founded by Canada's Centre for Commercialization of Regenerative Medicine (CCRM) and later joined, in partnership, by MEDIPOST, Co., Ltd., OmniaBio deploys over a decade of manufacturing and analytical technology expertise, developed through Canadian, U.S. and international partnerships.
OmniaBio will collaborate with pharmaceutical and biotech companies and academic centres to deliver comprehensive services from process, analytical and associated AI development to commercial manufacturing.
The new facility's first commercial-stage customer, MEDIPOST, is a recognized innovator in stem cell therapeutics and has plans to manufacture CARTISTEM® at OmniaBio's Hamilton site for North American patients. CARTISTEM is an allogeneic (sourced from donor cells) umbilical cord blood-derived mesenchymal stem cell product used to treat knee cartilage defects in patients with osteoarthritis caused by degeneration.
The new 120,000 sq. ft. site, located at McMaster Innovation Park and in close proximity to the U.S. border and Canada's largest international airport, is designed to meet specialized needs such as critical cold chain logistics, dedicated staff training infrastructure, intelligently designed production flows, and a multi-modality layout facilitating both cell and vector-focused manufacturing. Using advanced technologies such as robotics, biosensors and machine learning, OmniaBio will be among the first CDMOs globally to integrate these capabilities into its service offering, helping to reduce costs, improve product quality and increase production rates compared to conventional CDMO approaches. OmniaBio's AI-enabled manufacturing will first focus on cellular immunotherapies and iPSC-based therapies.
Quotes:
"I'm thrilled to celebrate the grand opening of OmniaBio's new centre of excellence in Hamilton, which will help create good-paying jobs for Ontario workers and cement our province's role as a world leader in life sciences. This new centre, which our government was proud to support through Invest Ontario, highlights the substantial increase in jobs and investment we've seen in Ontario's life sciences sector and points to the incredible opportunity this sector holds for our province's long-term prosperity."
- Hon. Doug Ford, Premier of Ontario
"With a highly-skilled workforce and competitive business environment, Ontario is a prime location for businesses in the life sciences sector to invest and grow. We congratulate OmniaBio on this exciting milestone and look forward to seeing their facility drive further advancements across the province's life sciences ecosystem."
- Hon. Vic Fedeli, Minister of Economic Development, Job Creation and Trade
"OmniaBio is partnering with clients to make these essential therapies more accessible and affordable for patients in North America and worldwide. This new facility puts us in a unique position as a specialist commercial CGT manufacturing leader tackling the toughest disease challenges head-on by combining an experienced team with advanced tools and solutions."
- Mitchel Sivilotti, President and CEO, OmniaBio Inc.
"The opening of OmniaBio's facility in Hamilton is an exciting milestone in CCRM's efforts to build a strong industry in Canada around its strengths in regenerative medicine, including cell and gene therapy. This facility is a game-changer as it will keep revolutionary companies in Canada and attract global leaders to our ecosystem. With manufacturing, we have the ingredients to see the ecosystem thrive."
- Michael May, President and CEO of CCRM and Chair of OmniaBio's Board.
"For two decades, MEDIPOST has been advancing cord blood stem cell therapies from basic science to successful commercialization. As demonstrated by the recent complete enrollment of our Phase III CARTISTEMTM trial in Japan and our plan for a Phase III trial in the U.S. MEDIPOST is fast becoming a global company, and our investment in OmniaBio is an investment in this future and in the people of Ontario who will help bring this vision to fruition."
- Antonio Lee, Global President, MEDIPOST, Co. Ltd. & Co-CEO and Director, MEDIPOST Inc.
"The opening of OmniaBio's Hamilton site is the result of the vision, determination, and collaboration of many dedicated people from across the globe. As the first client at this site, MEDIPOST looks forward to harnessing OmniaBio's world-class expertise and manufacturing capabilities to bring our stem cell therapy, CARTISTEM, to North America."
- Edward Ahn, CEO, MEDIPOST, Inc. (USA)
About OmniaBio
OmniaBio Inc. is a technology-focused, global cell and gene therapy CDMO with a vision to manufacture a disease-free world. As a subsidiary of CCRM, OmniaBio harnesses over a decade of expertise in regenerative medicine and advanced therapies. Offering comprehensive and tailored CDMO services, cutting-edge development and reliable Good Manufacturing Practices capabilities, OmniaBio specializes in immune cell-based therapies, induced pluripotent stem cell therapies and lentiviral vectors, driving advancements in the field and bringing maturity to cell and gene therapy. With existing clinical and commercial manufacturing capabilities OmniaBio is poised to meet surging global CGT manufacturing demand, enabling access to transformative treatments for patients around the world. Please visit us at www.omniabio.com to learn more.
About CCRM
CCRM is a global, public-private partnership headquartered in Canada. It has received funding from the Government of Canada, the Province of Ontario, and leading academic and industry partners. CCRM supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, investors, and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients with specialized teams, dedicated funding, and unique infrastructure. In 2022, CCRM established OmniaBio Inc., a commercial-stage CDMO for manufacturing cell and gene therapies. CCRM is hosted by the University of Toronto. Visit us at ccrm.ca.
About MEDIPOST
Founded in 2000, MEDIPOST is a leading commercial-stage biotechnology company specializing in the development of umbilical cord-derived stem cell therapies to treat inflammation-driven degenerative diseases. The company's flagship product, CARTISTEM®, is the world's first allogeneic stem cell therapy for knee osteoarthritis (OA), approved in Korea in 2012 and used to treat over 31,000 patients. As the largest and most trusted umbilical cord blood bank in Korea, MEDIPOST leverages its deep expertise in stem cell research and development to pioneer innovative treatments that improve patient outcomes. In partnership with the Centre for Commercialization of Regenerative Medicine (CCRM), MEDIPOST has established Omniabio, a cell and gene therapy contract development and manufacturing organization (CDMO) based in Hamilton, Ontario. With a focus on global expansion, MEDIPOST is advancing its therapies into the Japanese, U.S. and European markets through ongoing Phase III clinical programs.
For more information, please contact:
Stacey Johnson
Vice President, Communications and Marketing
CCRM and OmniaBio Inc.
stacey.johnson@omniabio.com
1-647-309-1830
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
OmniaBio Announces Opening of New Commercial Manufacturing Facility in Canada, Bringing Life-Saving Cell and Gene Therapies to Patients
OmniaBio Announces Opening of New Commercial Manufacturing Facility in Canada, Bringing Life-Saving Cell and Gene Therapies to Patients
OmniaBio Announces Opening of New Commercial Manufacturing Facility in Canada, Bringing Life-Saving Cell and Gene Therapies to Patients
